<DOC>
	<DOCNO>NCT02194556</DOCNO>
	<brief_summary>This randomise , control , open-label , prospective trial design assess efficacy safety icotinib maintenance therapy sequential Icotinib plus chemotherapy versus Icotinib maintenance therapy chemotherapy stage IIIB/IV non-small cell lung cancer patient EGFR mutation .</brief_summary>
	<brief_title>Sequential Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Stage IV IIIB advance nonsmall cell lung cancer patient Positive EGFR Mutation Nonprogressive disease firstline gemcitabine/cisplatin therapy Measurable lesion accord RECIST 1.1 least one measurable lesion Previous antiEGFR ( epidermal growth factor receptor ) monoclonal antibody small molecular agent gefitinib , erlotinib Patients wildtype EGFR Evidence interstitial lung disease Severe hypersensitivity icotinib excipients product . Evidence significant clinical disorder laboratory find make undesirable subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>